ADAMTS13 Activity <5%: Critical Diagnostic Finding for Thrombotic Thrombocytopenic Purpura
An ADAMTS13 activity level <5% is diagnostic for thrombotic thrombocytopenic purpura (TTP) in the appropriate clinical context and represents a medical emergency requiring immediate treatment initiation to prevent mortality from microvascular thrombosis and multi-organ ischemic damage. 1
Immediate Clinical Significance
A value <5% indicates severe ADAMTS13 deficiency, which is the pathophysiological hallmark of TTP. This severe deficiency prevents the normal cleavage of ultra-large von Willebrand factor (UL-VWF) multimers, leading to:
- Excessive platelet adhesion and aggregation throughout the microcirculation
- Widespread microvascular thrombus formation causing ischemic organ damage
- Potential mortality if untreated—historically nearly 100% fatal, now >95% survival with appropriate treatment 2
Diagnostic Algorithm
When ADAMTS13 activity returns <5%, proceed as follows:
1. Confirm Clinical Context
Look for the characteristic pentad (though not all need be present):
- Severe thrombocytopenia (typically <30 × 10⁹/L) 1
- Microangiopathic hemolytic anemia with schistocytes, elevated LDH, low hemoglobin/hematocrit
- Neurological symptoms (confusion, stroke, seizures)
- Renal impairment (though often milder in severe ADAMTS13 deficiency) 3
- Fever
Critical caveat: Do not wait for all five features—TTP can present with thrombocytopenia and hemolytic anemia alone. The diagnosis should be considered with ADAMTS13 <10% in proper clinical context 1.
2. Differentiate TTP Subtype
Test for anti-ADAMTS13 antibodies (inhibitors):
Antibodies present → Immune TTP (iTTP) - acquired autoimmune disease 1
Antibodies absent → Consider congenital TTP (cTTP) 1
- Requires genetic testing for ADAMTS13 mutations (~250 known mutations)
- Repeat antibody testing after therapy to confirm
- Can present in neonates/children OR remain asymptomatic until adulthood 2
Important pitfall: Absence of detectable antibodies during acute episodes does NOT rule out iTTP—free antibodies may be undetectable due to ELISA limitations or accelerated clearance of antibody-ADAMTS13 complexes [1, @24@].
3. Exclude Secondary Causes
ADAMTS13 <5% is highly specific for idiopathic TTP. Studies show:
- 0% of HUS patients have ADAMTS13 <5% 4
- 0% of stem cell transplant-associated TMA have ADAMTS13 <5% 4
- Only 2 of 17 patients with secondary TMA (cancer/chemotherapy) had ADAMTS13 <5% 4
If ADAMTS13 <5%, the diagnosis is almost certainly primary TTP (immune or congenital), not secondary TMA 5, 4, 6.
Prognostic Implications
Mortality Risk
- Idiopathic TTP with ADAMTS13 <5%: 15% mortality 5
- Patients with ADAMTS13 >25%: 59% mortality (likely secondary TMA with worse prognosis) 5
Treatment Response Predictors
Without inhibitors: Plasma exchange effectively raises ADAMTS13 levels and achieves complete clinical remission 5
With high-titer inhibitors (>5 units/mL):
- ADAMTS13 levels fail to rise despite plasma exchange
- Inhibitor titers remain elevated
- 75% experience recurrent disease or death 5
- Requires aggressive immunosuppression
Clinical Phenotype with ADAMTS13 <5%
Compared to patients with detectable ADAMTS13 activity, those with <5% have:
- Lower platelet counts (median 12 vs 49.5 × 10⁹/L) 3
- Less severe renal failure (GFR 78 vs 15.8 mL/min) 3
- Lower risk of end-stage renal disease (3.2% vs 21.4%) 3
- More autoimmune manifestations (polyarthritis, lupus-like features, positive autoantibodies) 3
Treatment Implications
Do not wait for ADAMTS13 results to initiate treatment—turnaround time can be several days, and TTP is immediately life-threatening 2.
For Immune TTP (iTTP):
- Therapeutic plasma exchange (TPE) daily until platelet recovery
- Corticosteroids (high-dose)
- Rituximab for immunosuppression
- Caplacizumab (anti-VWF nanobody) to accelerate recovery 1
For Congenital TTP (cTTP):
- Recombinant ADAMTS13 is now the strong recommendation over fresh frozen plasma (2025 ISTH guidelines) 1
- If recombinant ADAMTS13 unavailable, use fresh frozen plasma for prophylaxis
- Lifelong replacement therapy required
Key Clinical Pearls
ADAMTS13 <5% is ~60% sensitive for clinically diagnosed TTP but highly specific when present 4
Severe ADAMTS13 deficiency alone may not be sufficient to cause acute TTP—environmental triggers or additional genetic factors may be required 2
Schistocytes may be absent despite TTP diagnosis—do not rely solely on blood smear 2
Use clinical scoring systems (French score or PLASMIC score) while awaiting ADAMTS13 results to assess likelihood of severe deficiency 1
Monitor ADAMTS13 activity serially during treatment—failure to rise suggests high-titer inhibitors and poor prognosis 5